Roanna Ruiz
Stock Analyst at Leerink Partners
(0.74)
# 4,023
Out of 5,090 analysts
59
Total ratings
30.77%
Success rate
-17.53%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.20 | +66.67% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.51 | +38.25% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.54 | +354.55% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $10.56 | +70.45% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.40 | -28.57% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $6.50 | +207.69% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $9.93 | +171.90% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $6.38 | +103.76% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.98 | +134.11% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $489.31 | -32.56% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $65.67 | -11.68% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $86.11 | -70.97% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $14.60 | +235.62% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.17 | +89.27% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $35.26 | -46.11% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $63.30 | +89.57% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $9.99 | +400.50% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $16.54 | +141.84% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.20
Upside: +66.67%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.51
Upside: +38.25%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.54
Upside: +354.55%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $10.56
Upside: +70.45%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.40
Upside: -28.57%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $6.50
Upside: +207.69%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $9.93
Upside: +171.90%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $6.38
Upside: +103.76%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.98
Upside: +134.11%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $489.31
Upside: -32.56%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $65.67
Upside: -11.68%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $86.11
Upside: -70.97%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $14.60
Upside: +235.62%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.17
Upside: +89.27%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $35.26
Upside: -46.11%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $63.30
Upside: +89.57%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $9.99
Upside: +400.50%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $16.54
Upside: +141.84%